AbbVie stemt ermee in om $ 24 mln te betalen om de rechtszaak tegen Humira California op te lossen – Reutersaugustus 6, 2020
CBD Olie kan helpen bij artrose. Lees hoe op MHBioShop.com
Huile de CBD peut aider avec l’arthrose. Visite HuileCBD.be
A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014. Shire said on July 18 that it had accepted an offer of 32 billion pounds ($54.7 billion) from AbbVie. The U.S. pharmaceutical company will pay 24.44 pounds in cash and 0.8960 of a new AbbVie share for each Shire share. REUTERS/Brendan McDermid (UNITED STATES – Tags: BUSINESS)
(Reuters) – AbbVie Inc has agreed to pay $24 million to settle a lawsuit that alleged insurance fraud by the drugmaker in promoting its blockbuster drug Humira, California’s insurance regulator said on Thursday.
AbbVie denied the allegations, but agreed to look into how Humira is marketed to health care providers in the state, the regulator said
The Insurance Commissioner of California said the company also agreed to disclose that AbbVie, and not a medical provider, paid the registered nurses who are employed as so-called AbbVie Ambassadors to interact with patients about Humira.
Insurance Commissioner Ricardo Lara said AbbVie has paid $24 million to California and the whistleblower, a registered nurse who brought the case to the department’s attention in October 2016.
AbbVie did not immediately respond to Reuters request for comment.
Humira, the company’s flagship arthritis treatment, brought in sales of $3.97 billion in the latest quarter. It has been the major driver of AbbVie’s growth in the recent years but faces expirations of its patents in U.S. in 2023.
Among other things, the department alleged AbbVie violated California’s Insurance Frauds Prevention Act by unlawfully providing free and valuable professional goods and services to physicians to induce and reward Humira prescriptions.
Reporting by Vishwadha Chander in Bengaluru; Editing by Shailesh Kuber